{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:58:05Z","timestamp":1791496685834,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the expression of programmed death ligand-1 (PD-L1) and the levels of CD8<jats:sup>+<\/jats:sup> tumor-infiltrating lymphocytes (TILs) in meningioma as well as determine the association between their levels and the clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective case-control study on 93 patients with meningioma. The patients showed tumor recurrence and were matched with the control patients without recurrence in their age, gender, admission time, tumor sites, tumor volume, peritumoral brain edema (PTBE), Simpson grade resection, WHO grade, postoperative radiotherapy, and the follow-up duration. We reviewed the clinical data of patients and performed immunohistochemistry analysis to investigate the PD-L1 expression and the levels of CD8<jats:sup>+<\/jats:sup> TILs. Multivariate logistic regression was performed to analyze the association between clinical features and immune markers. The conditional logistic regression models were used to calculate the odds ratios (ORs) with 95% confidence intervals (CIs), and Kaplan\u2013Meier analysis was performed to analyze tumor recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Tumor volume was correlated with the PD-L1 expression (<jats:italic>P<\/jats:italic>\u2009=\u20090.003, HR\u2009=\u20095.288, 95%CI, 1.786\u201315.651). PTBE served as an independent predictor of CD8<jats:sup>+<\/jats:sup> TIL levels (<jats:italic>P<\/jats:italic>\u2009=\u20090.001, HR\u2009=\u20090.176, 95%CI 0.065\u20130.477). The levels of CD8<jats:sup>+<\/jats:sup> TILs were associated with tumor recurrence (<jats:italic>P<\/jats:italic>\u2009=\u20090.020, OR\u2009=\u20090.325, 95%CI, 0.125\u20130.840).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tumor volume was associated with PD-L1 expression, and PTBE was an independent predictor of CD8<jats:sup>+<\/jats:sup> TIL levels in meningioma. CD8<jats:sup>+<\/jats:sup> TIL levels correlated with tumor recurrence in meningioma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10249-4","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T17:04:19Z","timestamp":1668272659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Programmed death ligand 1 and tumor-infiltrating CD8+ T lymphocytes are associated with the clinical features in meningioma"],"prefix":"10.1186","volume":"22","author":[{"given":"Yaochuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanhan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"10249_CR1","doi-asserted-by":"crossref","unstructured":"Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021;9(3):319.","DOI":"10.3390\/biomedicines9030319"},{"issue":"11","key":"10249_CR2","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821\u201334.","journal-title":"Neuro Oncol"},{"key":"10249_CR3","doi-asserted-by":"publisher","first-page":"568931","DOI":"10.3389\/fimmu.2020.568931","volume":"11","author":"K Hudson","year":"2020","unstructured":"Hudson K, Cross N, Jordan-Mahy N, Leyland R. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol. 2020;11:568931.","journal-title":"Front Immunol"},{"issue":"8","key":"10249_CR4","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.4049\/jimmunol.1401572","volume":"193","author":"S Ostrand-Rosenberg","year":"2014","unstructured":"Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol (Baltimore, Md : 1950). 2014;193(8):3835\u201341.","journal-title":"J Immunol"},{"issue":"328","key":"10249_CR5","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324.","journal-title":"Sci Transl Med"},{"issue":"2","key":"10249_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"FK Dermani","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234(2):1313\u201325.","journal-title":"J Cell Physiol"},{"issue":"10274","key":"10249_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M, Bondarenko I, \u00d6zg\u00fcro\u011flu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592\u2013604.","journal-title":"Lancet"},{"issue":"5","key":"10249_CR8","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.3802\/jgo.2017.28.e64","volume":"28","author":"X Zhu","year":"2017","unstructured":"Zhu X, Lang J. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. J Gynecol Oncol. 2017;28(5):e64.","journal-title":"J Gynecol Oncol"},{"issue":"14","key":"10249_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"key":"10249_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58\u201367.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10249_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","volume":"13","author":"PK Brastianos","year":"2022","unstructured":"Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022;13(1):1325.","journal-title":"Nat Commun"},{"key":"10249_CR12","doi-asserted-by":"publisher","first-page":"h988","DOI":"10.1136\/bmj.h988","volume":"350","author":"LH Butterfield","year":"2015","unstructured":"Butterfield LH. Cancer vaccines. BMJ. 2015;350:h988.","journal-title":"BMJ"},{"key":"10249_CR13","doi-asserted-by":"crossref","unstructured":"Huang B, Liu R, Wang P, Yuan Z, Yang J, Xiong H, et al. CD8(+)CD57(+) T cells exhibit distinct features in human non-small cell lung cancer. J Immunother Cancer. 2020;8(1):e000639.","DOI":"10.1136\/jitc-2020-000639"},{"key":"10249_CR14","doi-asserted-by":"publisher","first-page":"748277","DOI":"10.3389\/fonc.2021.748277","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Song Y, Hu T, Wang X, Jiang Y, Zhang D, et al. Decreased CD8(+) lymphocytic infiltration in multifocal and multicentric glioblastomas. Front Oncol. 2021;11:748277.","journal-title":"Front Oncol"},{"issue":"10","key":"10249_CR15","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1038\/bjc.2014.162","volume":"110","author":"S Han","year":"2014","unstructured":"Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, et al. Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014;110(10):2560\u20138.","journal-title":"Br J Cancer"},{"issue":"6382","key":"10249_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"7","key":"10249_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","volume":"11","author":"W Yu","year":"2020","unstructured":"Yu W, Hua Y, Qiu H, Hao J, Zou K, Li Z, et al. PD-L1 promotes tumor growth and progression by activating WIP and \u03b2-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis. 2020;11(7):506.","journal-title":"Cell Death Dis"},{"issue":"8","key":"10249_CR18","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","volume":"22","author":"H Gevensleben","year":"2016","unstructured":"Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate Cancer. Clin Cancer Res. 2016;22(8):1969\u201377.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10249_CR19","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"10249_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","volume":"108","author":"C Wu","year":"2006","unstructured":"Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19\u201324.","journal-title":"Acta Histochem"},{"issue":"1","key":"10249_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10143-017-0897-x","volume":"42","author":"M Berhouma","year":"2019","unstructured":"Berhouma M, Jacquesson T, Jouanneau E, Cotton F. Pathogenesis of peri-tumoral edema in intracranial meningiomas. Neurosurg Rev. 2019;42(1):59\u201371.","journal-title":"Neurosurg Rev"},{"issue":"6","key":"10249_CR22","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2013.8.FOCUS13301","volume":"35","author":"J Hou","year":"2013","unstructured":"Hou J, Kshettry VR, Selman WR, Bambakidis NC. Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus. 2013;35(6):E2.","journal-title":"Neurosurg Focus"},{"issue":"4","key":"10249_CR23","first-page":"344","volume":"38","author":"YS Ding","year":"2008","unstructured":"Ding YS, Wang HD, Tang K, Hu ZG, Jin W, Yan W. Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann Clin Lab Sci. 2008;38(4):344\u201351.","journal-title":"Ann Clin Lab Sci"},{"issue":"4","key":"10249_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581\u2013611.","journal-title":"Endocr Rev"},{"issue":"6","key":"10249_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248\u201364.","journal-title":"Cell"},{"issue":"6","key":"10249_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607\u201315.","journal-title":"Nat Med"},{"issue":"1","key":"10249_CR27","doi-asserted-by":"publisher","first-page":"14115","DOI":"10.1038\/s41598-020-70514-z","volume":"10","author":"S Karimi","year":"2020","unstructured":"Karimi S, Mansouri S, Mamatjan Y, Liu J, Nassiri F, Suppiah S, et al. Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression. Sci Rep. 2020;10(1):14115.","journal-title":"Sci Rep"},{"issue":"6","key":"10249_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-019-02342-8","volume":"68","author":"YD Li","year":"2019","unstructured":"Li YD, Veliceasa D, Lamano JB, Lamano JB, Kaur G, Biyashev D, et al. Systemic and local immunosuppression in patients with high-grade meningiomas. Cancer Immunol Immunother. 2019;68(6):999\u20131009.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10249_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","volume":"130","author":"SJ Han","year":"2016","unstructured":"Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, et al. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neuro-Oncol. 2016;130(3):543\u201352.","journal-title":"J Neuro-Oncol"},{"issue":"7","key":"10249_CR30","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.18632\/oncotarget.3082","volume":"6","author":"Z Du","year":"2015","unstructured":"Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6(7):4704\u201316.","journal-title":"Oncotarget"},{"issue":"17","key":"10249_CR31","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-19-0389","volume":"25","author":"C Rapp","year":"2019","unstructured":"Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C, et al. Cytotoxic T cells and their activation status are independent prognostic markers in Meningiomas. Clin Cancer Res. 2019;25(17):5260\u201370.","journal-title":"Clin Cancer Res"},{"key":"10249_CR32","doi-asserted-by":"crossref","unstructured":"Turner CP, McLay J, Hermans IF, Correia J, Bok A, Mehrabi N, et al. Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma. Pathology. 2022;54(4):417\u201324.","DOI":"10.1016\/j.pathol.2021.10.002"},{"issue":"5","key":"10249_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41416-019-0398-5","volume":"120","author":"SH Kim","year":"2019","unstructured":"Kim SH, Go SI, Song DH, Park SW, Kim HR, Jang I, et al. Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. Br J Cancer. 2019;120(5):547\u201354.","journal-title":"Br J Cancer"},{"issue":"2","key":"10249_CR34","doi-asserted-by":"publisher","first-page":"e13923","DOI":"10.1097\/MD.0000000000013923","volume":"98","author":"X Xu","year":"2019","unstructured":"Xu X, Tan Y, Qian Y, Xue W, Wang Y, Du J, et al. Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: a meta-analysis. Medicine. 2019;98(2):e13923.","journal-title":"Medicine"},{"issue":"6","key":"10249_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10249-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T17:06:21Z","timestamp":1668272781000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10249-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10249"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10249-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively using data obtained for clinical purposes. The institutional review board of the First Hospital of China Medical University approved this study (Approval No. 2022098) and written informed consent was obtained from all meningioma tissue donors who willingly agreed to the use of their tumor tissues and clinical data for future research. All methods were performed in accordance with the relevant guidelines and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1171"}}